Press Releases 3 Investor Relations Press Releases Events Presentations Press Releases Year None20232022202120202019201820172016 Jan 27, 2023 DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Investor Tools Print Email Page Email Alerts RSS Feeds Contact IR
Press Releases Year None20232022202120202019201820172016 Jan 27, 2023 DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
